Literature DB >> 33423269

The association between serum homocysteine and depression: A systematic review and meta-analysis of observational studies.

Fatemeh Moradi1, Keyhan Lotfi2, Maryam Armin3, Cain C T Clark4, Gholamreza Askari3, Mohammad Hossein Rouhani3.   

Abstract

BACKGROUND: Hyperhomocysteinaemia is known to interfere with neurological functions; however, there is a controversy regarding the relationship between homocysteine and depression.
MATERIALS AND METHODS: Science Direct, MEDLINE and ISI Web of Science were searched to find relevant articles, published up to August 2020. Studies were included if they compared homocysteine levels in healthy subjects with subjects with depression. Also, articles that reported the association between hyperhomocysteinaemia and risk of depression were included. Odds ratios of depression and means of homocysteine were used to ascertain the overall effect size.
RESULTS: Homocysteine level was higher in subjects with depression in comparison with healthy controls (weight mean difference = 2.53 µmol/L, 95% confidence interval: 1.77, 3.30), and the depression diagnostic tool was a source of heterogeneity. Homocysteine level was significantly higher in subjects with depression in studies that used Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV), Geriatric Depression Scale (GDS), Zung Self-Rating Depression Scale (ZDRS) and Beck Depression Index II (BDI-II) as depression diagnostic tools. Also, participants with hyperhomocysteinaemia had a higher chance of depression (Pooled risk = 1.34, 95% confidence interval: 1.19, 1.52), where the depression diagnostic tool was a source of heterogeneity. In contrast to ZDRS and Patient Health Questionnaire (PHQ) subgroups, hyperhomocysteinaemia yielded a significantly higher risk of depression in DSM-IV, GDS and 'other' subgroups.
CONCLUSION: Homocysteinemia level is higher in individuals with depression. However, the depression diagnostic tool used is instrumental in influencing their association, and thus, future studies should focus on the tools for depression assessment.
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  depression; homocysteine; hyperhomocysteinaemia; meta-analysis; systematic review

Mesh:

Substances:

Year:  2021        PMID: 33423269     DOI: 10.1111/eci.13486

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

Review 1.  Mechanisms affecting brain remodeling in depression: do all roads lead to impaired fibrinolysis?

Authors:  Silvia Hoirisch-Clapauch
Journal:  Mol Psychiatry       Date:  2021-08-17       Impact factor: 15.992

2.  The association between major dietary patterns and severe mental disorders symptoms among a large sample of adults living in central Iran: Baseline data of YaHS-TAMYZ cohort study.

Authors:  Shamim Shams-Rad; Reza Bidaki; Azadeh Nadjarzadeh; Amin Salehi-Abargouei; Barbora de Courten; Masoud Mirzaei
Journal:  BMC Public Health       Date:  2022-06-04       Impact factor: 4.135

3.  Intrinsic Capacity Declines with Elevated Homocysteine in Community-Dwelling Chinese Older Adults.

Authors:  Siyang Lin; Fang Wang; Jiaxin Zheng; Yin Yuan; Feng Huang; Pengli Zhu
Journal:  Clin Interv Aging       Date:  2022-07-07       Impact factor: 3.829

4.  Maternal Mental Health in Late Pregnancy and Longitudinal Changes in Postpartum Serum Vitamin B-12, Homocysteine, and Milk B-12 Concentration Among Brazilian Women.

Authors:  Mônica Araujo Batalha; Paula Normando Dos Reis Costa; Ana Lorena Lima Ferreira; Nathalia C Freitas-Costa; Amanda C Cunha Figueiredo; Setareh Shahab-Ferdows; Daniela Hampel; Lindsay H Allen; Rafael Pérez-Escamilla; Gilberto Kac
Journal:  Front Nutr       Date:  2022-07-11

5.  The role of BDNF exon I region methylation in the treatment of depression with sertraline and its clinical diagnostic value.

Authors:  Yuhua Xing; Ting Sun; Guangxue Li; Guoan Xu; Jia Cheng; Shugui Gao
Journal:  J Clin Lab Anal       Date:  2021-09-15       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.